Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Dalcetrapib

Drug and asset intelligence for Dalcetrapib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

DalCor Pharmaceuticals →

Recent signals(1)

ClinicalJune 23, 2026

Phase 3 Trial of Dalcetrapib in ACS Patients with AA Genotype Initiated by DalCor Pharmaceuticals

DalCor Pharmaceuticals is initiating a phase 3 trial evaluating the effect of Dalcetrapib on cardiovascular risk in patients with recent acute coronary syndrome (ACS) and a specific genetic profile.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

DalCor Pharmaceuticals — Dalcetrapib

Monitor enrollment rates and preliminary results from the trial, particularly the efficacy data related to the AA genotype.

June 23, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiovascular →

Cardiovascular · ACS →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.